Pharma and Biotech Daily: Navigating the Ever-Evolving Landscape

Good morning from Pharma and Biotech daily: the podcast that gives you only what's important to hear in Pharma e Biotech world.Eli Lilly's oral weight loss pill, orfoglipron, has faced challenges in meeting expectations, possibly due to an over-representation of males and Hispanic patients in the phase III study. The company is now presenting detailed late-stage data to paint a competitive profile for the drug. Meanwhile, the FDA has targeted Lilly and Novo Nordisk for downplaying risks of their GLP-1 weight loss drugs in advertising, particularly during a prime time special with Oprah Winfrey. Lilly is also investing in a $5 billion manufacturing plant in Virginia, part of a larger $27 billion U.S. investment plan.In other news, GSK is committing $30 billion to boost R&D and manufacturing operations in the U.S., showing a strong commitment to innovation. Additionally, advancements in AI-driven antibody discovery technology by Sino Biological are revolutionizing the field of biotechnology. The pharmaceutical industry is facing tightening oversight and regulatory changes, as well as exploring predictive care powered by consumers and AI technology.This dynamic landscape highlights the importance of staying informed and adaptable in the ever-evolving world of Pharma and Biotech.

Support the show